NewAmsterdam Pharma Co N.V. files 10-Q

NewAmsterdam Pharma reported a net loss of $48.4 million for the first quarter of 2026, a decrease from the $39.5 million loss in the same period last year, primarily due to increased research and development expenses. The company's cash and cash equivalents and marketable securities totaled $707.3 million as of March 31, 2026, which management believes is sufficient to fund its operations.